Vasopressin Interactions: Alcohol, Caffeine, Food and Other Compounds in the Published Literature

What "interaction" means in the vasopressin literature

Vasopressin (arginine vasopressin, AVP) appears in two very different research literatures, and the word interaction means something different in each. In critical care and anaesthesia, vasopressin has been studied as an intravenous vasoactive agent given alongside other drugs, so "interaction" describes drug combinations compared in trials — for example vasopressin with epinephrine during cardiopulmonary resuscitation, examined in a 2005 resuscitation analysis (PMID 16039036). In neuroscience and addiction research, "interaction" usually means how a substance such as ethanol changes endogenous vasopressin signalling, as reviewed in a 2018 paper describing alcohol and the vasopressin system as a multifaceted relationship (PMID 30392132).

Because of that split, questions about everyday substances — caffeine, food timing, fasting — rarely map onto any published vasopressin interaction trial. Where the verified literature contains no such study, this page says so and labels any explanation as mechanistic reasoning rather than a reported result. Background on the peptide itself sits on the vasopressin overview.

Vasopressin and alcohol: what studies report

Reviews of the two-way relationship

Alcohol is the most studied substance in relation to vasopressin. A 2018 Psychopharmacology review characterised vasopressin and alcohol as a multifaceted relationship, covering both how ethanol alters vasopressin signalling and how vasopressin systems contribute to alcohol-related behaviour (PMID 30392132). A companion 2018 review in the Journal of Neuroendocrinology examined the effects of alcohol and psychostimulants on the vasopressin system and the behavioural implications researchers drew from those changes (PMID 29802803). Neither review described a consumer-style "combination"; both described ethanol exposure as a modifier of an endogenous neuropeptide system.

Alcohol use disorder research

A 2024 chapter in International Review of Neurobiology reviewed the role of oxytocin and vasopressin in alcohol use disorder, treating the two neuropeptides as parallel targets within preclinical and translational addiction research (PMID 39523056). A related review in Current Topics in Behavioral Neurosciences examined the relationship between oxytocin and alcohol dependence, a literature that frequently sits alongside vasopressin work because the two peptides share closely related receptor families (PMID 37697074). The broader translational framing for both peptides — their distribution and behavioural roles in the human brain — was set out in a 2011 Nature Reviews Neuroscience review of oxytocin and vasopressin as social neuropeptides (PMID 21852800).

Alcohol, fluid balance and hangover

Vasopressin's antidiuretic function is the reason alcohol appears in fluid-balance discussions at all. A 2010 review of the pathology of alcohol hangover discussed dehydration among the candidate mechanisms of hangover symptoms and connected it to alcohol's effect on vasopressin-driven water retention (PMID 20712596). The same review reported that hangover pathology was not explained by any single mechanism, with inflammatory and metabolic contributors also discussed (PMID 20712596).

A separate line of clinical work looked at drinking patterns in an inner-ear condition in which vasopressin has been hypothesised to matter: a study of alcohol consumption in Menière's disease patients examined drinking habits in that population rather than administering alcohol or vasopressin (PMID 29733259). Researchers in that paper worked with self-reported consumption data, so it described an association within a patient group and not a controlled interaction experiment (PMID 29733259).

What the alcohol literature does not contain

None of the verified alcohol papers tested administered vasopressin together with alcohol in humans to measure a combined clinical outcome; the 2018 reviews instead synthesised ethanol's effects on endogenous vasopressin signalling and vasopressin-related behaviour (PMID 30392132, PMID 29802803). That distinction matters: a review of how a drug perturbs a hormone system is not evidence about co-administration safety, and the reviews did not present it as such (PMID 39523056).

Vasopressin and caffeine: no interaction study in this evidence set

There is no study in the verified literature on this page that examined caffeine together with vasopressin, in humans or in animals. No dose, no timing relationship and no outcome can be reported, because none was measured.

Mechanistic reasoning (not a study finding): researchers interested in this question generally start from the fact that vasopressin acts at renal V2 receptors to promote water reabsorption, while caffeine is commonly discussed as a mild diuretic. Any hypothesis that the two oppose each other at the level of urine output is therefore a prediction from physiology, not a reported result. The closest verified material is descriptive work on vasopressin's clinical pharmacology in intensive care, which reviewed the agent's vascular and renal actions in critically ill patients rather than any caffeine comparison (PMID 15616384).

Food, fasting and fluid intake

Likewise, no verified paper tested vasopressin with a specific diet, meal timing or fasting protocol. Vasopressin release in healthy physiology is governed by plasma osmolality and blood volume, which is why hydration and sodium intake are the variables investigators usually model — but that framing is mechanistic reasoning, and the papers cited here did not run such an experiment.

Two adjacent sources are worth separating from it. The Menière's disease work examined dietary alcohol intake in a patient group in which fluid regulation is a research interest, and reported consumption patterns rather than a dietary intervention (PMID 29733259). And in the renal–cardiovascular literature, the 2026 DAPA-BODY trial reported that an SGLT2 inhibitor required co-administration with diuretics to effectively reduce interstitial fluid retention, a study about body-fluid compartments and drug combinations rather than about peptide supplementation (PMID 41034569).

Other compounds studied alongside vasopressin

Catecholamines in resuscitation and surgery

The best-documented co-administration literature for vasopressin is hospital-based. A 2005 Resuscitation paper examined epinephrine and vasopressin during cardiopulmonary resuscitation, comparing vasopressor strategies in cardiac arrest (PMID 16039036). A 2014 case-based review of cardiac arrest discussed vasopressor choice within resuscitation algorithms as part of its clinical teaching format (PMID 25225579). In the operating room, a 2019 review in the Journal of Cardiac Surgery covered vasopressin therapy in cardiac surgery, including its use in vasoplegic states where catecholamine requirements are high (PMID 30597665). An earlier Current Opinion in Critical Care review surveyed vasopressin in the ICU across shock states and summarised the evidence available at that time (PMID 15616384).

All four of these describe intravenous administration by clinicians to acutely unwell patients under continuous monitoring (PMID 30597665, PMID 16039036). They are not models for any other context, and the reviews did not generalise beyond their clinical settings (PMID 15616384).

Diuretics and fluid-handling drugs

Drugs that alter renal water handling are the most mechanistically obvious neighbours to vasopressin. The verified evidence here is indirect: the DAPA-BODY trial reported on the combination of an SGLT2 inhibitor with diuretics and its effect on interstitial fluid retention (PMID 41034569). That trial did not administer vasopressin, so it offers context about fluid-compartment pharmacology rather than a vasopressin interaction result (PMID 41034569).

Psychostimulants

Beyond alcohol, the 2018 neuroendocrinology review also covered psychostimulant effects on the vasopressin system and the behavioural implications researchers attached to them (PMID 29802803). As with alcohol, that work concerned how a drug of abuse altered endogenous vasopressin signalling, not a supplementation combination (PMID 29802803).

Evidence map

Vasopressin Combinations and Adverse Events: What Studies Report

Adverse-event reporting for vasopressin in the verified set comes almost entirely from the critical-care literature, where the drug was given intravenously under monitoring. The 2019 cardiac surgery review discussed vasopressin therapy in that surgical population, including the haemodynamic considerations clinicians weigh when it is used with other vasoactive agents (PMID 30597665). The ICU review similarly summarised vasopressin's clinical profile across shock states (PMID 15616384), and the 2005 resuscitation paper reported on epinephrine and vasopressin use during cardiopulmonary resuscitation (PMID 16039036). A 2014 case-based review placed these agents within cardiac arrest management (PMID 25225579).

On the alcohol side, the reviews reported neuroendocrine and behavioural changes in experimental models rather than adverse events from a vasopressin product (PMID 30392132, PMID 29802803). No verified paper catalogued adverse events from combining vasopressin with caffeine, food, or fasting, because no such study was conducted.

How to read gaps in this literature

• Absence of a study is not absence of an effect. It means no measurement exists to report.
• Mechanistic plausibility is a hypothesis. Reasoning from receptor biology — as the ICU review described vasopressin's vascular and renal actions (PMID 15616384) — generates predictions, not findings.
• Context does not transfer. Intravenous use in cardiac surgery (PMID 30597665) and ethanol exposure in rodent neuroscience (PMID 29802803) answer different questions.
• Related peptides are not interchangeable. Oxytocin findings in alcohol dependence (PMID 37697074) sit beside vasopressin work (PMID 21852800) without substituting for it.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, medication or substance. It summarises what published studies examined and reported, and does not recommend, endorse or describe any personal use.

References

• Vasopressin and alcohol: a multifaceted relationship (Psychopharmacology, 2018)
• Effects of alcohol and psychostimulants on the vasopressin system: behavioral implications (Journal of Neuroendocrinology, 2018)
• Role of oxytocin and vasopressin in alcohol use disorder (International Review of Neurobiology, 2024)
• The Relationship Between Oxytocin and Alcohol Dependence (Current Topics in Behavioral Neurosciences, 2025)
• The pathology of alcohol hangover (Current Drug Abuse Reviews, 2010)
• Alcohol consumption in Menière's disease patients (Nutritional Neuroscience, 2020)
• Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine (Nature Reviews Neuroscience, 2011)
• Vasopressin therapy in cardiac surgery (Journal of Cardiac Surgery, 2019)
• Vasopressin in the ICU (Current Opinion in Critical Care, 2004)
• Epinephrine and vasopressin during cardiopulmonary resuscitation (Resuscitation, 2005)
• Cardiac arrest: a case-based review (World Journal of Emergency Medicine, 2014)
• SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial (Hypertension Research, 2026)